NCI/NIH Award $2 Million to Immunicom to Initiate Clinical Trial Evaluating Breakthrough Immunopheresis® LW-02 Molecular Subtractive Therapy in Refractory ER+/Her2- Breast Cancer
Grant will support Company’s first US-based clinical trial, to be conducted at Baylor College of Medicine New Immunopheresis® therapeutic molecular ligand-capture platform is designed to activate endogenous antitumor pathways by removing factors shed by cancer cells that suppress immune response and promote cancer growth The Company’s fourth clinical trial seeks to provide important safety, efficacy, … [Read more…]
